ProCE Banner Activity

CE / CME

Improving Management of Atopic Dermatitis in Children and Adults With Novel Therapies – Part 1

Video

Atopic dermatitis (AD) affects people of all ages, races, and ethnicities and has a substantial psychosocial impact on patients and their relatives. Fortunately, treatment options for AD are expanding with the emergence of innovative biologic and small-molecule therapies targeted specifically against disease processes, with other treatments in development. Tune in this first of a 3-part, on-demand webcast series to hear about new and emerging therapies for patients of all ages with AD.  

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: November 22, 2022

Expiration: November 21, 2023

No longer available for credit.

Share

Faculty

Victoria Garcia-Albea

Victoria Garcia-Albea, PNP, DCNP

Director, Lahey Dermatology Nurse Practitioner Training Program
Lahey Dermatology
Burlington, Massachusetts

Benjamin Ungar

Benjamin Ungar, MD

Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Assistant Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from Incyte and Sanofi and Regeneron Pharmaceuticals.

Incyte

Sanofi and Regeneron Pharmaceuticals

Target Audience

Dermatologists and NPs, PAs, physicians, and nurses who practice in dermatology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients who may benefit from new and emerging therapies for atopic dermatitis based on patient factors and drug safety and efficacy

Disclosure

All faculty and planners participating in continuing education activities sponsored by Clinical Care Options, LLC (CC) and Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to CCO and PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

Robert Sidbury, MD, MPH: consultant/advisor/speaker: Beiersdorf, Leo, Lilly.

Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis, Castle Biosciences; researcher: Incyte, Pfizer, Rapt Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC, Partners for Advancing Clinical Education, and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Victoria Garcia-Albea, NP, DCNP and Kristine Kucera, PA-C, MPAS, DHSc, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

    1. View the content in its entirety
    2. Relate the content material to the learning objectives
    3. Complete evaluation form

The estimated time to complete this activity is 0.50 hours.

Format

This program has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Clinical Care Options, LLC, Partners for Advancing Clinical Education, Practicing Clinicians Exchange,  or any educational supporter.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
NP course advisor: Victoria Garcia-Albea, NP, DCNP, Lahey Hospital and Medical Center, Burlington, Massachusetts

 

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until November 21, 2023. PAs should only claim credit commensurate with the extent of their participation. 

PA course advisor: Kristine Kucera, PA-C, MPAS, DHSc, UT Southwestern Medical Center, Dallas Texas

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.